200a/b/c
|
High expression in ovarian cancer samples
|
[7,8,10]
|
|
High expression correlated with decreased progression-free survival
|
[8]
|
|
Decreased in tumors with high β-tubulin III levels
|
[33]
|
200a
|
Increased in 43% of primary ovarian carcinomas, associated with high-grade and late-stage tumors
|
[9]
|
|
High expression correlated with recurrence free survival and, or, overall survival
|
[34,35]
|
|
Increased tumour growth, targets p38α and modulates oxidative stress signature
|
[34]
|
|
Sensitized tumors to paclitaxel
|
[34]
|
200c
|
Targeted TUBB3 for degradation leading to increased paclitaxel sensitivity
|
[36]
|
|
Low levels associated with incomplete response to paclitaxel–carboplatin chemotherapy and recurrence
|
[33]
|
|
Decreased adhesion to basement membrane complex
|
[36]
|
|
Repressed ZEB1, decreased migration and invasion in HEY cells |
[36] |